Updates to CMS' Medicare Advantage (MA) Value-Based Insurance Design (VBID) model broaden the scope of the existing model by testing a wide range of MA service delivery and/or payment approaches.
This article was collaboratively written by A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design (V-BID), and several V-BID Center staff.
In January, CMS released major changes to the current Medicare Advantage (MA) Value-Based Insurance Design (VBID) model. Starting in 2020, and running through 2024, these updates are intended to lower costs while increasing the quality and coverage of care for Medicare beneficiaries.
The original MA VBID model, launched in 2017, was designed to allow MA plans the opportunity to offer supplemental benefits or reduced cost-sharing for enrollees with certain chronic conditions who engage with services/providers that are of highest clinical value to them.
The updated model, coined “VBID 2.0,” broadens the scope of the existing model by testing a wide range of MA service delivery and/or payment approaches including:
Additionally, CMS will allow for testing of the inclusion of Medicare’s hospice benefits into MA beginning in 2021. More details on the hospice carve-in are to be released.
The VBID 2.0 updates reflect President Trump’s HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs and demonstrate the growing support for structuring benefit designs to encourage the use of high-value evidence-based services and providers.
“Today’s announcement draws on successes we have already seen in Medicare and advances our priority of using HHS programs to build a value-driven healthcare system,” said HHS Secretary Alex Azar.
Through increased testing of clinically nuanced strategies in MA plan benefit designs, the MA VBID model continues to evaluate the effectiveness of aligning out-of-pocket costs with the clinical value of services, with the goals of improving health outcomes and lowering expenditures for MA enrollees.